Iron Chelation Therapy for Malaria
Identifieur interne : 002612 ( Main/Exploration ); précédent : 002611; suivant : 002613Iron Chelation Therapy for Malaria
Auteurs : George F. Mabeza [Zimbabwe] ; Mark Loyevsky [États-Unis] ; Victor R. Gordeuk [États-Unis] ; Günter Weiss [Autriche]Source :
- Pharmacology and Therapeutics [ 0163-7258 ] ; 1999.
English descriptors
- Teeft :
- Acad, Agents chemother, Aikawa, Aminolevulinate synthase, Animal models, Antimalarial, Antimalarial action, Antimalarial activity, Antimalarial agents, Antimalarial drugs, Antimalarial effect, Antimalarial therapy, Antiparasitic effect, Aotus monkeys, Aromatic chelators, Asexual, Beneficial effect, Beneficial effects, Berghei, Bind iron, Biochem, Biol, Blood cell, Brittenham, Cabantchik, Cell membrane, Cerebral, Cerebral malaria, Cerebral malaria patients, Chelation, Chelator, Chelators, Churchill livingstone, Clin, Coma, Confidence interval, Coordination sites, Cytokine, Cytotoxic, Cytotoxicity, Deep coma, Deferiprone, Derivative, Desferrioxamine, Dos, Drapier, Early schizonts, Effector, Elsevier science, Erythrocyte, Erythrocytic, Erythrocytic phase, Erythrocytic trophozoite, Falciparum, Falciparum malaria, Falciparum parasitemia, Ferritin, Food vacuole, Free radicals, Fritsch, Full consciousness, Glickstein, Gordeuk, Haematol, Helper type, Heme, Hemoglobin, Hemorrhagic injury, Heppner, Hershko, Hibbs, High affinity, Hnfbh, Host defense, Host hemoglobin, Human macrophages, Human malaria, Human monocytes, Hydrazone, Immune, Immune function, Immune response, Immunol, Infection, Infusion, Inhibitory, Inhibitory effect, Interferon, Intracellular, Iron, Iron chelation, Iron chelation therapy, Iron chelator, Iron chelators, Iron deficiency, Iron metabolism, Iron overload, Iron withholding, Isonicotinoyl, Labile, Labile pool, Late trophozoite, Libman, Life cycle, Lipophilicity, Loading dose, Loyevsky, Lytton, Mabeza, Macrophage, Malaria, Malaria cultures, Malaria parasites, Malarial, Mammalian cells, Metabolic processes, Metabolism, Mitochondrial, Mrna, Natl, Neopterin, Nitric, Nitric oxide, Nitric oxide synthase, Oxide, Parasite, Parasite clearance, Parasite growth, Parasitemia, Parasitic infections, Parasitized, Parasitized erythrocytes, Parasitol, Parasitophorous, Parasitophorous vacuole, Pathogenesis, Pathway, Peroxidant, Peto, Pharmacol, Placebo, Plasma levels, Plasma transferrin, Plasmodial, Plasmodium, Plasmodium falciparum, Plasmodium falciparum malaria, Pollack, Ponka, Proc, Quinine, Recent study, Receptor, Reductase, Ribonucleotide, Ribonucleotide reductase, Rodriguez, Sadrzadeh, Salicylaldehyde isonicotinoyl hydrazone, Scheibel, Schizonts, Serum concentrations, Severe malaria, Shanzer, Siderophores, Single agent, Subcellular membranes, Synthase, Thuma, Toxic complexes, Transferrin, Transferrin receptors, Transferrin saturation, Transferrin saturations, Trophozoite, Tsafack, Tumor cells, Tumor necrosis factor, Uncomplicated, Uncomplicated falciparum, Unpublished observations, Vacuole, Vivax, Vivax malaria, Wachter, Weiss, Withholding iron, World health organization, Yinnon, Zambian children.
Abstract
Abstract: Malaria is one of the major global health problems, and an urgent need for the development of new antimalarial agents faces the scientific community. A considerable number of iron(III) chelators, designed for purposes other than treating malaria, have antimalarial activity in vitro, apparently through the mechanism of withholding iron from vital metabolic pathways of the intra-erythrocytic parasite. Certain iron(II) chelators also have antimalarial activity, but the mechanism of action appears to be the formation of toxic complexes with iron rather than the withholding of iron. Several of the iron(III)-chelating compounds also have antimalarial activity in animal models of plasmodial infection. Iron chelation therapy with desferrioxamine, the only compound of this nature that is widely available for use in humans, has clinical activity in both uncomplicated and severe malaria in humans.
Url:
DOI: 10.1016/S0163-7258(98)00037-0
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002214
- to stream Istex, to step Curation: 002214
- to stream Istex, to step Checkpoint: 001427
- to stream Main, to step Merge: 002648
- to stream Main, to step Curation: 002612
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Iron Chelation Therapy for Malaria</title>
<author><name sortKey="Mabeza, George F" sort="Mabeza, George F" uniqKey="Mabeza G" first="George F" last="Mabeza">George F. Mabeza</name>
</author>
<author><name sortKey="Loyevsky, Mark" sort="Loyevsky, Mark" uniqKey="Loyevsky M" first="Mark" last="Loyevsky">Mark Loyevsky</name>
</author>
<author><name sortKey="Gordeuk, Victor R" sort="Gordeuk, Victor R" uniqKey="Gordeuk V" first="Victor R" last="Gordeuk">Victor R. Gordeuk</name>
</author>
<author><name sortKey="Weiss, Gunter" sort="Weiss, Gunter" uniqKey="Weiss G" first="Günter" last="Weiss">Günter Weiss</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8E574E592257E2C1BA52C8AD66312053838F77FE</idno>
<date when="1999" year="1999">1999</date>
<idno type="doi">10.1016/S0163-7258(98)00037-0</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-9VTTZMLD-D/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002214</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002214</idno>
<idno type="wicri:Area/Istex/Curation">002214</idno>
<idno type="wicri:Area/Istex/Checkpoint">001427</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001427</idno>
<idno type="wicri:doubleKey">0163-7258:1999:Mabeza G:iron:chelation:therapy</idno>
<idno type="wicri:Area/Main/Merge">002648</idno>
<idno type="wicri:Area/Main/Curation">002612</idno>
<idno type="wicri:Area/Main/Exploration">002612</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Iron Chelation Therapy for Malaria</title>
<author><name sortKey="Mabeza, George F" sort="Mabeza, George F" uniqKey="Mabeza G" first="George F" last="Mabeza">George F. Mabeza</name>
<affiliation wicri:level="1"><country xml:lang="fr">Zimbabwe</country>
<wicri:regionArea>Department Of Medicine, University Of Zimbabwe Medical School, P.o. Box A178, Avondale, Harare</wicri:regionArea>
<wicri:noRegion>Harare</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Loyevsky, Mark" sort="Loyevsky, Mark" uniqKey="Loyevsky M" first="Mark" last="Loyevsky">Mark Loyevsky</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department Of Medicine, The George Washington University Medical Center, Suite 428, 2150 Pennsylvania Avenue Nw, Washington, Dc 20037</wicri:regionArea>
<wicri:noRegion>Dc 20037</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gordeuk, Victor R" sort="Gordeuk, Victor R" uniqKey="Gordeuk V" first="Victor R" last="Gordeuk">Victor R. Gordeuk</name>
<affiliation wicri:level="1"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department Of Medicine, The George Washington University Medical Center, Suite 428, 2150 Pennsylvania Avenue Nw, Washington, Dc 20037</wicri:regionArea>
<wicri:noRegion>Dc 20037</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Weiss, Gunter" sort="Weiss, Gunter" uniqKey="Weiss G" first="Günter" last="Weiss">Günter Weiss</name>
<affiliation wicri:level="1"><country xml:lang="fr">Autriche</country>
<wicri:regionArea>Department Of Internal Medicine, University Of Innsbruck, Innsbruck</wicri:regionArea>
<wicri:noRegion>Innsbruck</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Pharmacology and Therapeutics</title>
<title level="j" type="abbrev">JPT</title>
<idno type="ISSN">0163-7258</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1999">1999</date>
<biblScope unit="volume">81</biblScope>
<biblScope unit="issue">1</biblScope>
<biblScope unit="page" from="53">53</biblScope>
<biblScope unit="page" to="75">75</biblScope>
</imprint>
<idno type="ISSN">0163-7258</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0163-7258</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Acad</term>
<term>Agents chemother</term>
<term>Aikawa</term>
<term>Aminolevulinate synthase</term>
<term>Animal models</term>
<term>Antimalarial</term>
<term>Antimalarial action</term>
<term>Antimalarial activity</term>
<term>Antimalarial agents</term>
<term>Antimalarial drugs</term>
<term>Antimalarial effect</term>
<term>Antimalarial therapy</term>
<term>Antiparasitic effect</term>
<term>Aotus monkeys</term>
<term>Aromatic chelators</term>
<term>Asexual</term>
<term>Beneficial effect</term>
<term>Beneficial effects</term>
<term>Berghei</term>
<term>Bind iron</term>
<term>Biochem</term>
<term>Biol</term>
<term>Blood cell</term>
<term>Brittenham</term>
<term>Cabantchik</term>
<term>Cell membrane</term>
<term>Cerebral</term>
<term>Cerebral malaria</term>
<term>Cerebral malaria patients</term>
<term>Chelation</term>
<term>Chelator</term>
<term>Chelators</term>
<term>Churchill livingstone</term>
<term>Clin</term>
<term>Coma</term>
<term>Confidence interval</term>
<term>Coordination sites</term>
<term>Cytokine</term>
<term>Cytotoxic</term>
<term>Cytotoxicity</term>
<term>Deep coma</term>
<term>Deferiprone</term>
<term>Derivative</term>
<term>Desferrioxamine</term>
<term>Dos</term>
<term>Drapier</term>
<term>Early schizonts</term>
<term>Effector</term>
<term>Elsevier science</term>
<term>Erythrocyte</term>
<term>Erythrocytic</term>
<term>Erythrocytic phase</term>
<term>Erythrocytic trophozoite</term>
<term>Falciparum</term>
<term>Falciparum malaria</term>
<term>Falciparum parasitemia</term>
<term>Ferritin</term>
<term>Food vacuole</term>
<term>Free radicals</term>
<term>Fritsch</term>
<term>Full consciousness</term>
<term>Glickstein</term>
<term>Gordeuk</term>
<term>Haematol</term>
<term>Helper type</term>
<term>Heme</term>
<term>Hemoglobin</term>
<term>Hemorrhagic injury</term>
<term>Heppner</term>
<term>Hershko</term>
<term>Hibbs</term>
<term>High affinity</term>
<term>Hnfbh</term>
<term>Host defense</term>
<term>Host hemoglobin</term>
<term>Human macrophages</term>
<term>Human malaria</term>
<term>Human monocytes</term>
<term>Hydrazone</term>
<term>Immune</term>
<term>Immune function</term>
<term>Immune response</term>
<term>Immunol</term>
<term>Infection</term>
<term>Infusion</term>
<term>Inhibitory</term>
<term>Inhibitory effect</term>
<term>Interferon</term>
<term>Intracellular</term>
<term>Iron</term>
<term>Iron chelation</term>
<term>Iron chelation therapy</term>
<term>Iron chelator</term>
<term>Iron chelators</term>
<term>Iron deficiency</term>
<term>Iron metabolism</term>
<term>Iron overload</term>
<term>Iron withholding</term>
<term>Isonicotinoyl</term>
<term>Labile</term>
<term>Labile pool</term>
<term>Late trophozoite</term>
<term>Libman</term>
<term>Life cycle</term>
<term>Lipophilicity</term>
<term>Loading dose</term>
<term>Loyevsky</term>
<term>Lytton</term>
<term>Mabeza</term>
<term>Macrophage</term>
<term>Malaria</term>
<term>Malaria cultures</term>
<term>Malaria parasites</term>
<term>Malarial</term>
<term>Mammalian cells</term>
<term>Metabolic processes</term>
<term>Metabolism</term>
<term>Mitochondrial</term>
<term>Mrna</term>
<term>Natl</term>
<term>Neopterin</term>
<term>Nitric</term>
<term>Nitric oxide</term>
<term>Nitric oxide synthase</term>
<term>Oxide</term>
<term>Parasite</term>
<term>Parasite clearance</term>
<term>Parasite growth</term>
<term>Parasitemia</term>
<term>Parasitic infections</term>
<term>Parasitized</term>
<term>Parasitized erythrocytes</term>
<term>Parasitol</term>
<term>Parasitophorous</term>
<term>Parasitophorous vacuole</term>
<term>Pathogenesis</term>
<term>Pathway</term>
<term>Peroxidant</term>
<term>Peto</term>
<term>Pharmacol</term>
<term>Placebo</term>
<term>Plasma levels</term>
<term>Plasma transferrin</term>
<term>Plasmodial</term>
<term>Plasmodium</term>
<term>Plasmodium falciparum</term>
<term>Plasmodium falciparum malaria</term>
<term>Pollack</term>
<term>Ponka</term>
<term>Proc</term>
<term>Quinine</term>
<term>Recent study</term>
<term>Receptor</term>
<term>Reductase</term>
<term>Ribonucleotide</term>
<term>Ribonucleotide reductase</term>
<term>Rodriguez</term>
<term>Sadrzadeh</term>
<term>Salicylaldehyde isonicotinoyl hydrazone</term>
<term>Scheibel</term>
<term>Schizonts</term>
<term>Serum concentrations</term>
<term>Severe malaria</term>
<term>Shanzer</term>
<term>Siderophores</term>
<term>Single agent</term>
<term>Subcellular membranes</term>
<term>Synthase</term>
<term>Thuma</term>
<term>Toxic complexes</term>
<term>Transferrin</term>
<term>Transferrin receptors</term>
<term>Transferrin saturation</term>
<term>Transferrin saturations</term>
<term>Trophozoite</term>
<term>Tsafack</term>
<term>Tumor cells</term>
<term>Tumor necrosis factor</term>
<term>Uncomplicated</term>
<term>Uncomplicated falciparum</term>
<term>Unpublished observations</term>
<term>Vacuole</term>
<term>Vivax</term>
<term>Vivax malaria</term>
<term>Wachter</term>
<term>Weiss</term>
<term>Withholding iron</term>
<term>World health organization</term>
<term>Yinnon</term>
<term>Zambian children</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: Malaria is one of the major global health problems, and an urgent need for the development of new antimalarial agents faces the scientific community. A considerable number of iron(III) chelators, designed for purposes other than treating malaria, have antimalarial activity in vitro, apparently through the mechanism of withholding iron from vital metabolic pathways of the intra-erythrocytic parasite. Certain iron(II) chelators also have antimalarial activity, but the mechanism of action appears to be the formation of toxic complexes with iron rather than the withholding of iron. Several of the iron(III)-chelating compounds also have antimalarial activity in animal models of plasmodial infection. Iron chelation therapy with desferrioxamine, the only compound of this nature that is widely available for use in humans, has clinical activity in both uncomplicated and severe malaria in humans.</div>
</front>
</TEI>
<affiliations><list><country><li>Autriche</li>
<li>Zimbabwe</li>
<li>États-Unis</li>
</country>
</list>
<tree><country name="Zimbabwe"><noRegion><name sortKey="Mabeza, George F" sort="Mabeza, George F" uniqKey="Mabeza G" first="George F" last="Mabeza">George F. Mabeza</name>
</noRegion>
</country>
<country name="États-Unis"><noRegion><name sortKey="Loyevsky, Mark" sort="Loyevsky, Mark" uniqKey="Loyevsky M" first="Mark" last="Loyevsky">Mark Loyevsky</name>
</noRegion>
<name sortKey="Gordeuk, Victor R" sort="Gordeuk, Victor R" uniqKey="Gordeuk V" first="Victor R" last="Gordeuk">Victor R. Gordeuk</name>
</country>
<country name="Autriche"><noRegion><name sortKey="Weiss, Gunter" sort="Weiss, Gunter" uniqKey="Weiss G" first="Günter" last="Weiss">Günter Weiss</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002612 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002612 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= ChloroquineV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:8E574E592257E2C1BA52C8AD66312053838F77FE |texte= Iron Chelation Therapy for Malaria }}
This area was generated with Dilib version V0.6.33. |